Article

OBJECTIVE: To systematically review the effectiveness of oral baclofen versus
placebo or other antispastic oral medications in terms of body function, level of
activity, and quality of life in children and adolescents with spastic cerebral
palsy who are younger than 18 years. DATA SOURCES: Cochrane Library, Health
Science Databases, DARE, LILACS, Embase, MEDLINE, OTseeker, PEDro, PsycINFO,
SpeechBITE, ScienceDirect, Scopus, Trip, ClinicalTrials.gov, Google Scholar,
OpenGrey, and manual search. STUDY SELECTION: Randomized or not randomized
controlled trials and cohort studies comparing the effect of any dosage of oral
baclofen with that of no treatment, placebo, or another antispastic medication in
children and adolescents with spastic cerebral palsy were selected. DATA
EXTRACTION: Following the Cochrane Handbook for Systematic Reviews of
Interventions guidelines, 2 reviewers independently searched articles in
databases from their inceptions until October 2014. DATA SYNTHESIS: Six
randomized controlled trials involving a total of 130 patients were selected.
Studies show a great variability in motor classification, dosage of baclofen, and
outcome measures. There is conflicting evidence on the effectiveness of oral
baclofen in reducing muscle tone or improving motor function or the level of
activity. The overall methodological quality of the studies was low. The main
qualitative limitations of the studies correspond to serious risk of bias,
inconsistency of results, unpowered sample size, and publication bias.
CONCLUSIONS: There are insufficient data to support or refute the use of oral
baclofen for reducing spasticity or improving motor function in children and
adolescents with spastic cerebral palsy.
CI - Copyright (c) 2016 American Congress of Rehabilitation Medicine. Published by
Elsevier Inc. All rights reserved.

Langue : ANGLAIS